感染

订阅

MedSci主页 / 所有栏目 / 感染

AIM：两种新型HIV-1预防疫苗的安全性和免疫原性评价

2016-02-03 MedSci MedSci原创

HIV-1预防疫苗安全性免疫原性
关注

预防性HIV疫苗是一个全球性的健康优先的选择。该研究的目的是评估一种新型疫苗平台作为预防HIV-1方案的效果。研究人员进行了一项随机性，双盲，安慰剂对照试验，参与者和研究人员都不知道治疗分配。该研究在美国，东非，南非进行。参与者为非HIV感染的年轻成人。干预措施为2种HIV-1疫苗（腺病毒血清型26包含HIV-1 A插入[Ad26.EnvA]和腺病毒血清型35包含HIV-1 A插入[Ad35.En

预防性HIV疫苗是一个全球性的健康优先的选择。该研究的目的是评估一种新型疫苗平台作为预防HIV-1方案的效果。

研究人员进行了一项随机性，双盲，安慰剂对照试验，参与者和研究人员都不知道治疗分配。该研究在美国，东非，南非进行。参与者为非HIV感染的年轻成人。

干预措施为2种HIV-1疫苗（腺病毒血清型26包含HIV-1 A插入[Ad26.EnvA]和腺病毒血清型35包含HIV-1 A插入[Ad35.Env]，两种疫苗的剂量均为5×10 e10病毒颗粒）同源和异源的组合。

主要结果为基线向量免疫的安全性和免疫原性及效果。

217名参与者接受至少1次接种疫苗，210（>96％）名完成随访。没有疫苗相关的严重不良事件发生。所有方案的一般耐受性良好。所有方案在几乎所有的参与者中都引起体液免疫和细胞免疫应答。预先存在的Ad26-或Ad35的中和抗体滴度对疫苗安全性和免疫原性没有影响。在同源和异源的方案中，第二次接种显著增加Enva抗体滴度（从30-300到3000的平均酶联免疫吸附滴度检测大约为20倍）。 AD26-Ad35的异源方案比Ad35-AD26引起显著更高的ENVA抗体滴度。东非与南非和美国相比，T细胞的反应是温和的。

两种疫苗在所有人群显著均引起免疫反应。基线向量免疫力没有显著影响反应。在所有的方案第二次接种显著增加了Enva抗体滴度，尽管在异源方案疫苗顺序对免疫应答影响不大。

原始出处：

Baden LR, Karita E, Mutua G,et al.Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention,ANN INTERN MED,2016.2.2

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820139, encodeId=6c2e182013926, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri May 20 03:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63500, encodeId=f1936350005, content=有些可信, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Feb 06 12:07:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63388, encodeId=3a4e6338833, content=分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 14:31:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393786, encodeId=42311393e8665, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402573, encodeId=16ea14025e3f7, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444134, encodeId=5475144413410, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-05-20 surilei

    #预防疫苗#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1820139, encodeId=6c2e182013926, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri May 20 03:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63500, encodeId=f1936350005, content=有些可信, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Feb 06 12:07:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63388, encodeId=3a4e6338833, content=分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 14:31:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393786, encodeId=42311393e8665, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402573, encodeId=16ea14025e3f7, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444134, encodeId=5475144413410, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-02-06 忠诚向上

    有些可信

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1820139, encodeId=6c2e182013926, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri May 20 03:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63500, encodeId=f1936350005, content=有些可信, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Feb 06 12:07:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63388, encodeId=3a4e6338833, content=分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 14:31:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393786, encodeId=42311393e8665, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402573, encodeId=16ea14025e3f7, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444134, encodeId=5475144413410, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-02-05 1de47ca2m12(暂无匿称)

    分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1820139, encodeId=6c2e182013926, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri May 20 03:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63500, encodeId=f1936350005, content=有些可信, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Feb 06 12:07:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63388, encodeId=3a4e6338833, content=分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 14:31:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393786, encodeId=42311393e8665, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402573, encodeId=16ea14025e3f7, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444134, encodeId=5475144413410, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-02-05 ms5353107019656438

    #免疫原性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1820139, encodeId=6c2e182013926, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri May 20 03:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63500, encodeId=f1936350005, content=有些可信, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Feb 06 12:07:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63388, encodeId=3a4e6338833, content=分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 14:31:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393786, encodeId=42311393e8665, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402573, encodeId=16ea14025e3f7, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444134, encodeId=5475144413410, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-02-05 zhangying8789

    #防疫#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1820139, encodeId=6c2e182013926, content=<a href='/topic/show?id=143c100349b0' target=_blank style='color:#2F92EE;'>#预防疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100349, encryptionId=143c100349b0, topicName=预防疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e080359, createdName=surilei, createdTime=Fri May 20 03:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63500, encodeId=f1936350005, content=有些可信, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Feb 06 12:07:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63388, encodeId=3a4e6338833, content=分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Fri Feb 05 14:31:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393786, encodeId=42311393e8665, content=<a href='/topic/show?id=718528982e3' target=_blank style='color:#2F92EE;'>#免疫原性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28982, encryptionId=718528982e3, topicName=免疫原性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402573, encodeId=16ea14025e3f7, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444134, encodeId=5475144413410, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Feb 05 12:36:00 CST 2016, time=2016-02-05, status=1, ipAttribution=)]
    2016-02-05 huagfeg

    #评价#

    0